ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis

Idiopathic intracranial hypertension (pseudotumor cerebri): Epidemiology and pathogenesis
Literature review current through: Jan 2024.
This topic last updated: Feb 28, 2023.

INTRODUCTION — Idiopathic intracranial hypertension (IIH), also called pseudotumor cerebri, is a disorder defined by clinical criteria that include symptoms and signs isolated to those produced by increased intracranial pressure (ICP; eg, headache, papilledema, vision loss), elevated ICP with normal cerebrospinal fluid (CSF) composition, and no other cause of intracranial hypertension evident on neuroimaging or other evaluations [1].

While once called benign intracranial hypertension, to distinguish it from secondary intracranial hypertension produced by a neoplastic malignancy, it is not a benign disorder. Many patients with IIH suffer from headaches, which may be disabling, and there is a risk of severe, permanent vision loss.

While the pathogenesis of IIH is unknown, risk factors have been identified and many theories advanced as to its cause. The epidemiology and pathogenesis of IIH will be reviewed here. The clinical features, diagnosis, prognosis, and treatment of this disorder are discussed separately. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis" and "Idiopathic intracranial hypertension (pseudotumor cerebri): Prognosis and treatment".)

EPIDEMIOLOGY

Incidence — The annual incidence of IIH is 1 to 2 per 100,000 population [2,3]. There is a higher incidence in females with obesity between the ages of 15 and 44 years (4 to 21 per 100,000) [3,4]. The highest incidence, 28 per 100,000 per year, was reported in Ireland [5].

The incidence and prevalence of IIH are rising [6]; whether this is related to the obesity epidemic or other reasons is uncertain.

Risk factors — IIH is a disorder that primarily affects females of childbearing age who are overweight [3,4,7-11]. In a prospective study of 50 consecutively diagnosed IIH patients, 92 percent were females with a mean age of 31 years (range 11 to 58 years), and 94 percent were obese [10]. Other case series in different geographic areas and ethnic groups report similar findings [4,11-16].

IIH can also occur in males and in patients who are not overweight; it is also reported in children as young as four months and in older patients (up to 88 years) [15,17-20]. However, when symptoms occur in one of the less typical patient groups, the evaluation for secondary causes of intracranial hypertension is particularly important. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis", section on 'Differential diagnosis'.)

The annual incidence of IIH in children younger than 17 years old has been estimated as 0.63 per 100,000 children in the United States [21]. Risk factors are different in prepubertal children compared with adults. There is no female preponderance in young patients [17,22-30]. Also, prepubertal children with IIH are not more likely to be obese than the general age-matched population [22,23,26,27,29,30].

In one report, older patients (greater than 44 years) with IIH were also more often male and less often obese than patients with IIH in the more typical age range [31]. Males with IIH have a similar age distribution as females, and obesity remains a risk factor but may be less prevalent in males than in females with IIH [12,18].

Recent weight gain may be a risk factor for IIH, according to case-control studies [8,10,11,32]. In one series, there was an average reported weight gain of 1.8 kg over the two months preceding symptom onset [10]; in another series, there was an average 20 pound weight gain over the preceding year compared with an average weight loss of 1.2 pounds in controls [11].

In the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT), 5 percent of patients reported a family history of IIH [16]. As this frequency is higher than the prevalence of IIH in persons with obesity, a genetic component for IIH is suggested.

Associated conditions — Several systemic diseases, drugs, vitamin deficiencies and excesses, anemia [33,34], and hereditary conditions have been reported to be associated with IIH, but that association is uncommon.

The true link between these conditions and IIH is uncertain in many cases. In case-control studies, the prevalence of menstrual irregularities, pregnancy, antibiotic use, iron deficiency anemia, thyroid dysfunction, and oral contraceptive use was no different among cases versus controls [8,11]. However, these studies were small (40 to 50 patients), which may have limited their ability to detect true associations.

Medications — A number of medications and other exogenous substances have been linked to IIH. In some cases, the connection may be anecdotal. In other cases, evidence that supports a true association includes temporal proximity between drug initiation and IIH in a substantial number of patients, resolution with drug cessation or dose lowering, lack of recurrence off medication, and/or reemergence of IIH with drug rechallenge. Such evidence appears to exist for growth hormone, tetracyclines, and retinoids.

Growth hormone appears to be associated with IIH in a dose-related manner [35-41]. One 2007 study estimated the incidence of IIH in children treated with growth hormone to be 27.7 per 100,000 treatment years. This complication usually develops within one year of initiation of therapy but may appear after several years [42]. IIH generally subsides with stopping growth hormone therapy; resuming therapy at a lower dose is often successful. Other specific treatments for IIH may also be required [39]. (See "Treatment of growth hormone deficiency in children".)

Tetracyclines, including minocycline and doxycycline, have been linked in a number of cases to IIH, but other risk factors are often present [43-52]. When it occurs, IIH often appears shortly after onset of treatment (within a few weeks to months), but a more delayed onset has been described. Drug withdrawal appears to be sufficient for treatment in some patients.

Hypervitaminosis A from excessive dietary intake has been a long-known cause of IIH [43,53]. Other retinoids used in the treatment of dermatologic conditions and cancer therapy, all-trans retinoic acid, retinol, isotretinoin, etretinate, and tretinoin have also been reported to be associated with IIH [43,44,48,54-58].

More limited, possibly anecdotal evidence links other medications with IIH:

Thyroid replacement [25,59-61]

Corticosteroid withdrawal [31,62,63]

Lithium [64-67]

Nalidixic acid [26,68]

Nitrofurantoin [69,70]

Systemic illnesses — In addition to obesity, systemic illnesses reportedly associated with IIH include:

Addison disease [71,72]

Hypoparathyroidism [73]

Anemia, usually severe [15,33,74,75]

Sleep apnea [15,16,19,76,77]

Systemic lupus erythematosus (SLE) [78-80]

Behçet syndrome [81,82]

Polycystic ovary syndrome [83]

Coagulation disorders [83-86]

Uremia [87]

Hypovitaminosis A [88-91]

The pathogenic mechanisms associating these conditions with IIH are uncertain, and in some cases, the apparent association may be indirect or spurious. As an example, sleep apnea is associated with obesity and therefore may be secondarily associated with IIH. In SLE, cases of apparent IIH may be due to occult cerebral venous thrombosis (related to inflammation of the venous sinus or hypercoagulability) or to corticosteroid withdrawal [78]. Other hypercoagulable syndromes, sarcoidosis, and Behçet syndrome may also be associated with IIH by causing secondary intracranial hypertension via occult venous sinus thrombosis. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis", section on 'Differential diagnosis'.)

PATHOGENESIS — Although many theories for IIH have been proposed, the precise pathogenesis of IIH remains unknown. Any theory must account for the high incidence of IIH in obese females of childbearing years. Proposed etiologies include cerebral venous outflow abnormalities (eg, venous stenoses and venous hypertension); increased cerebrospinal fluid (CSF) outflow resistance at the level of either the arachnoid granulations or CSF lymphatic drainage sites; obesity-related increased abdominal and intracranial venous pressure; altered sodium and water retention mechanisms; and abnormalities of vitamin A metabolism [92].

Intracranial venous hypertension — Elevated intracranial venous pressure is postulated both as a primary mechanism and as a "final common pathway" for IIH. This theory is supported by the similar clinical appearances of IIH and secondary intracranial hypertension due to cerebral venous thrombosis and other causes of obstructed venous outflow. Some patients thought to have IIH have been later discovered to have one of these conditions [81,93-95]. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis", section on 'Differential diagnosis'.)

Although several authors have reported cerebral venous outflow abnormalities on magnetic resonance imaging (MRI) and magnetic resonance venography (MRV) in patients with IIH, there is some disagreement as to the frequency or the significance of these findings [20,96,97]. Clear venous sinus thrombosis has definite clinicopathologic significance, but apparent bilateral venous sinus narrowing or stenosis is now known to be a biomarker of increased intracranial pressure (ICP) [98]. Differentiation of venous stenosis from flow-related abnormalities, especially on noncontrast MRV, can be difficult, as flow-related artifacts can mimic venous sinus stenoses or even be mistaken for sinus thrombosis. These issues can sometimes be resolved with postcontrast MRV. Literature that suggests a high frequency of venous sinus abnormalities in patients with IIH must be viewed with caution.

Cerebral venous sinus structural abnormalities were systematically identified in a series of 29 patients with IIH using a specialized MRV technique, auto-triggered elliptic-centric-ordered three-dimensional gadolinium-enhanced MRV (ATECO MRV) [99]. Masked readers detected substantial bilateral sinovenous stenoses in 27 of 29 patients compared with 4 of 59 controls, corresponding to a sensitivity and specificity of 93 percent. The investigators speculated that congenital narrowing of the venous sinus might be a primary cause of IIH or alternatively a secondary, but potentially contributing, factor. In the latter scenario, increased CSF pressure compresses the transverse sinuses leading to the stenoses, which in turn would exacerbate the increased ICP, potentially bringing the patient to clinical presentation.

Other evidence leaves open the question of whether these apparent venous abnormalities are a secondary or a primary (causative) phenomenon. One study documented high intracranial venous sinus pressures in patients with IIH that were reduced by removal of CSF [100]. This finding implies that increased cerebral venous sinus pressure and apparent stenosis in IIH is caused by the elevated ICP and is not its cause. Other reports have also documented reversal of apparent transverse sinus stenosis after CSF shunting [101-106]. By contrast, other case series have documented persistent transverse sinus stenosis in patients with IIH whose CSF pressure has normalized and an overall poor correlation between the severity of the venous abnormalities and the degree of pressure elevation or severity of clinical findings [107,108].

Other theories — There is evidence that obesity increases intraabdominal pressure, pleural pressure, cardiac filling pressure, and central venous pressure and may lead to increased intracranial venous pressure and IIH [109]. Limited support for this theory comes from a report of seven obese females with IIH who reported subjective symptom relief with the use of an externally applied device that lowered abdominal pressure [110]. However, this mechanism does not account for the sex difference in IIH, the lack of increased incidence in pregnancy, and the cases of IIH in thin patients [111,112].

Cerebral edema was one of the earliest proposed mechanisms for IIH and had pathologic support in one case series [113]. However, subsequent pathologic and MRI studies have not found evidence of cerebral edema in patients with IIH [114-117]. A link between IIH and altered sodium and water retention was suggested by another report in which 77 percent of patients with IIH had evidence of peripheral edema and 80 percent had orthostatic retention of sodium and water [118]. Impaired excretion after water or saline load in the upright posture was noted in patients with IIH with orthostatic edema compared with lean patients with IIH and obese controls without IIH. However, the precise mechanisms linking orthostatic changes and IIH were not defined, and many patients with IIH do not have these sodium and water abnormalities.

Case reports of IIH occurring in association with vitamin A intoxication have suggested a role for vitamin A in the pathogenesis of IIH [43,53]. Elevated serum vitamin A, retinol, and retinol-binding protein levels have been reported in some patients with IIH [119,120]. In other studies, higher CSF vitamin A, retinol, and retinol-binding protein levels have been found in patients with IIH compared with controls [121-123]. One case-control study concluded vitamin A toxicity was an unlikely cause of IIH [124].

Other causes of impaired CSF absorption or increased CSF production have also been postulated as an etiology of IIH. As an example, one hypothesis proposes that microthrombosis in the sagittal sinus may block CSF absorption in the arachnoid granulations there, even in the absence of a thrombosis of sufficient size to be seen on neuroimaging studies [83,125]. Conditions that obstruct venous outflow (venous sinus thrombosis), impair CSF absorption (subarachnoid hemorrhage or infectious meningitis), and are associated with CSF overproduction (choroid plexus papilloma) can produce a syndrome similar to IIH. (See "Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis", section on 'Differential diagnosis'.)

Sleep apnea can be a complication of obesity and may play a role in IIH, perhaps in males in particular [19,126]. Hypercarbia may produce elevated ICP through vasodilation. Papilledema occurs in approximately 1 percent of patients with sleep apnea [127,128]. One study found that 14 of 37 patients with IIH had a sleep disturbance, and of these, 13 had evidence of sleep apnea or upper airway resistance syndrome [77]. In another report, a patient with IIH underwent ICP monitoring with pulse oximetry to reveal that apneic episodes were associated with marked elevations of ICP [129].

Several studies have looked at the pathophysiology of obesity and its complications as a basis for IIH. Leptin is a protein secreted by adipose cells in proportion to total body fat content. Higher serum leptin levels were found in 15 obese patients with IIH compared with 16 obese and 15 nonobese controls [130]. The pathophysiologic consequences of this finding are not known. Other studies of other adipokines, leptin, and the gastric hormone, ghrelin, have not consistently found an association with IIH [125,131].

Few studies have examined the potential role of sex hormones in IIH. In one study of eight males with IIH, two had abnormal estradiol levels, four had abnormal follicle-stimulating and luteinizing hormone levels, and seven had low testosterone levels [132].

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topics (see "Patient education: Idiopathic intracranial hypertension (pseudotumor cerebri) (The Basics)")

SUMMARY

Incidence and risk factors – The incidence of idiopathic intracranial hypertension (IIH) in the general population is 1 to 2 per 100,000 population and is 2 to 20 times higher in the primary risk group: overweight females of childbearing years. (See 'Epidemiology' above and 'Risk factors' above.)

Associated medications and medical illnesses – A long list of medications has been reported to be associated with IIH. The evidence linking growth hormone treatment, retinoids, and tetracycline antibiotics is strongest; however, the mechanisms by which these might produce IIH is not known. (See 'Medications' above.)

Other than obesity, the association between other medical conditions and IIH is not proven. (See 'Systemic illnesses' above.)

Theories of pathogenesis – The pathogenesis of IIH is unknown. Much attention has been placed on the association of IIH with venous sinus stenosis. However, most of the evidence at present suggests that apparent venous sinus narrowing is secondary to increased intracranial pressure (ICP) and is not the primary cause in most cases. (See 'Intracranial venous hypertension' above.)

Other theories include increased cerebrospinal fluid (CSF) outflow resistance, obesity-related increased abdominal and intracranial venous pressure, altered sodium and water retention mechanisms, and abnormalities of vitamin A metabolism. (See 'Other theories' above.)

ACKNOWLEDGMENT — The UpToDate editorial staff acknowledges Claudia Prospero Ponce, MD, and Aroucha Vickers, MD, who contributed to an earlier version of this topic review.

  1. Friedman DI, Jacobson DM. Diagnostic criteria for idiopathic intracranial hypertension. Neurology 2002; 59:1492.
  2. Durcan FJ, Corbett JJ, Wall M. The incidence of pseudotumor cerebri. Population studies in Iowa and Louisiana. Arch Neurol 1988; 45:875.
  3. Radhakrishnan K, Ahlskog JE, Cross SA, et al. Idiopathic intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol 1993; 50:78.
  4. Kesler A, Gadoth N. Epidemiology of idiopathic intracranial hypertension in Israel. J Neuroophthalmol 2001; 21:12.
  5. McCluskey G, Mulholland DA, McCarron P, McCarron MO. Idiopathic Intracranial Hypertension in the Northwest of Northern Ireland: Epidemiology and Clinical Management. Neuroepidemiology 2015; 45:34.
  6. Curry WT Jr, Butler WE, Barker FG 2nd. Rapidly rising incidence of cerebrospinal fluid shunting procedures for idiopathic intracranial hypertension in the United States, 1988-2002. Neurosurgery 2005; 57:97.
  7. Corbett JJ, Savino PJ, Thompson HS, et al. Visual loss in pseudotumor cerebri. Follow-up of 57 patients from five to 41 years and a profile of 14 patients with permanent severe visual loss. Arch Neurol 1982; 39:461.
  8. Ireland B, Corbett JJ, Wallace RB. The search for causes of idiopathic intracranial hypertension. A preliminary case-control study. Arch Neurol 1990; 47:315.
  9. Jain N, Rosner F. Idiopathic intracranial hypertension: report of seven cases. Am J Med 1992; 93:391.
  10. Wall M, George D. Idiopathic intracranial hypertension. A prospective study of 50 patients. Brain 1991; 114 ( Pt 1A):155.
  11. Giuseffi V, Wall M, Siegel PZ, Rojas PB. Symptoms and disease associations in idiopathic intracranial hypertension (pseudotumor cerebri): a case-control study. Neurology 1991; 41:239.
  12. Kesler A, Goldhammer Y, Gadoth N. Do men with pseudomotor cerebri share the same characteristics as women? A retrospective review of 141 cases. J Neuroophthalmol 2001; 21:15.
  13. Bruce BB, Preechawat P, Newman NJ, et al. Racial differences in idiopathic intracranial hypertension. Neurology 2008; 70:861.
  14. Galvin JA, Van Stavern GP. Clinical characterization of idiopathic intracranial hypertension at the Detroit Medical Center. J Neurol Sci 2004; 223:157.
  15. Bruce BB, Kedar S, Van Stavern GP, et al. Atypical idiopathic intracranial hypertension: normal BMI and older patients. Neurology 2010; 74:1827.
  16. Wall M, Kupersmith MJ, Kieburtz KD, et al. The idiopathic intracranial hypertension treatment trial: clinical profile at baseline. JAMA Neurol 2014; 71:693.
  17. Soler D, Cox T, Bullock P, et al. Diagnosis and management of benign intracranial hypertension. Arch Dis Child 1998; 78:89.
  18. Digre KB, Corbett JJ. Pseudotumor cerebri in men. Arch Neurol 1988; 45:866.
  19. Lee AG, Golnik K, Kardon R, et al. Sleep apnea and intracranial hypertension in men. Ophthalmology 2002; 109:482.
  20. Johnston I, Kollar C, Dunkley S, et al. Cranial venous outflow obstruction in the pseudotumour syndrome: incidence, nature and relevance. J Clin Neurosci 2002; 9:273.
  21. Gillson N, Jones C, Reem RE, et al. Incidence and Demographics of Pediatric Intracranial Hypertension. Pediatr Neurol 2017; 73:42.
  22. Balcer LJ, Liu GT, Forman S, et al. Idiopathic intracranial hypertension: relation of age and obesity in children. Neurology 1999; 52:870.
  23. Cinciripini GS, Donahue S, Borchert MS. Idiopathic intracranial hypertension in prepubertal pediatric patients: characteristics, treatment, and outcome. Am J Ophthalmol 1999; 127:178.
  24. Gordon K. Pediatric pseudotumor cerebri: descriptive epidemiology. Can J Neurol Sci 1997; 24:219.
  25. Lessell S. Pediatric pseudotumor cerebri (idiopathic intracranial hypertension). Surv Ophthalmol 1992; 37:155.
  26. Scott IU, Siatkowski RM, Eneyni M, et al. Idiopathic intracranial hypertension in children and adolescents. Am J Ophthalmol 1997; 124:253.
  27. Genizi J, Lahat E, Zelnik N, et al. Childhood-onset idiopathic intracranial hypertension: relation of sex and obesity. Pediatr Neurol 2007; 36:247.
  28. Warman R. Management of pseudotumor cerebri in children. Int Pediatr 2000; 15:147.
  29. Distelmaier F, Sengler U, Messing-Juenger M, et al. Pseudotumor cerebri as an important differential diagnosis of papilledema in children. Brain Dev 2006; 28:190.
  30. Per H, Canpolat M, Gümüş H, et al. Clinical spectrum of the pseudotumor cerebri in children: etiological, clinical features, treatment and prognosis. Brain Dev 2013; 35:561.
  31. Bandyopadhyay S, Jacobson DM. Clinical features of late-onset pseudotumor cerebri fulfilling the modified dandy criteria. J Neuroophthalmol 2002; 22:9.
  32. Salpietro V, Chimenz R, Arrigo T, Ruggieri M. Pediatric idiopathic intracranial hypertension and extreme childhood obesity: a role for weight gain. J Pediatr 2013; 162:1084.
  33. Biousse V, Rucker JC, Vignal C, et al. Anemia and papilledema. Am J Ophthalmol 2003; 135:437.
  34. Mollan SP, Ball AK, Sinclair AJ, et al. Idiopathic intracranial hypertension associated with iron deficiency anaemia: a lesson for management. Eur Neurol 2009; 62:105.
  35. Blethen SL. Complications of growth hormone therapy in children. Curr Opin Pediatr 1995; 7:466.
  36. Francois I, Casteels I, Silberstein J, et al. Empty sella, growth hormone deficiency and pseudotumour cerebri: effect of initiation, withdrawal and resumption of growth hormone therapy. Eur J Pediatr 1997; 156:69.
  37. Koller EA, Stadel BV, Malozowski SN. Papilledema in 15 renally compromised patients treated with growth hormone. Pediatr Nephrol 1997; 11:451.
  38. Malozowski S, Tanner LA, Wysowski DK, et al. Benign intracranial hypertension in children with growth hormone deficiency treated with growth hormone. J Pediatr 1995; 126:996.
  39. Rogers AH, Rogers GL, Bremer DL, McGregor ML. Pseudotumor cerebri in children receiving recombinant human growth hormone. Ophthalmology 1999; 106:1186.
  40. Maneatis T, Baptista J, Connelly K, Blethen S. Growth hormone safety update from the National Cooperative Growth Study. J Pediatr Endocrinol Metab 2000; 13 Suppl 2:1035.
  41. Reeves GD, Doyle DA. Growth hormone treatment and pseudotumor cerebri: coincidence or close relationship? J Pediatr Endocrinol Metab 2002; 15 Suppl 2:723.
  42. Vischi A, Guerriero S, Giancipoli G, et al. Delayed onset of pseudotumor cerebri syndrome 7 years after starting human recombinant growth hormone treatment. Eur J Ophthalmol 2006; 16:178.
  43. Friedman DI. Medication-induced intracranial hypertension in dermatology. Am J Clin Dermatol 2005; 6:29.
  44. Moskowitz Y, Leibowitz E, Ronen M, Aviel E. Pseudotumor cerebri induced by vitamin A combined with minocycline. Ann Ophthalmol 1993; 25:306.
  45. Sirdofsky M, Kattah J, Macedo P. Intracranial hypertension in a dieting patient. J Neuroophthalmol 1994; 14:9.
  46. Ang ER, Zimmerman JC, Malkin E. Pseudotumor cerebri secondary to minocycline intake. J Am Board Fam Pract 2002; 15:229.
  47. Chiu AM, Chuenkongkaew WL, Cornblath WT, et al. Minocycline treatment and pseudotumor cerebri syndrome. Am J Ophthalmol 1998; 126:116.
  48. Friedman DI, Gordon LK, Egan RA, et al. Doxycycline and intracranial hypertension. Neurology 2004; 62:2297.
  49. Gardner K, Cox T, Digre KB. Idiopathic intracranial hypertension associated with tetracycline use in fraternal twins: case reports and review. Neurology 1995; 45:6.
  50. Kesler A, Goldhammer Y, Hadayer A, Pianka P. The outcome of pseudotumor cerebri induced by tetracycline therapy. Acta Neurol Scand 2004; 110:408.
  51. Mochizuki K, Takahashi T, Kano M, et al. Pseudotumor cerebri induced by minocycline therapy for acne vulgaris. Jpn J Ophthalmol 2002; 46:668.
  52. Fraser CL, Biousse V, Newman NJ. Minocycline-induced fulminant intracranial hypertension. Arch Neurol 2012; 69:1067.
  53. Donahue SP. Recurrence of idiopathic intracranial hypertension after weight loss: the carrot craver. Am J Ophthalmol 2000; 130:850.
  54. Alemayehu W. Pseudotumor cerebri (toxic effect of the "magic bullet"). Ethiop Med J 1995; 33:265.
  55. Sharieff GQ, Hanten K. Pseudotumor cerebri and hypercalcemia resulting from vitamin A toxicity. Ann Emerg Med 1996; 27:518.
  56. Colucciello M. Pseudotumor cerebri induced by all-trans retinoic acid treatment of acute promyelocytic leukemia. Arch Ophthalmol 2003; 121:1064.
  57. Yeh YC, Tang HF, Fang IM. Pseudotumor cerebri caused by all-trans-retinoic acid treatment for acute promyelocytic leukemia. Jpn J Ophthalmol 2006; 50:295.
  58. Fraunfelder FW, Fraunfelder FT, Corbett JJ. Isotretinoin-associated intracranial hypertension. Ophthalmology 2004; 111:1248.
  59. Serratrice J, Granel B, Conrath J, et al. Benign intracranial hypertension and thyreostimulin suppression hormonotherapy. Am J Ophthalmol 2002; 134:910.
  60. Campos SP, Olitsky S. Idiopathic intracranial hypertension after L-thyroxine therapy for acquired primary hypothyroidism. Clin Pediatr (Phila) 1995; 34:334.
  61. Raghavan S, DiMartino-Nardi J, Saenger P, Linder B. Pseudotumor cerebri in an infant after L-thyroxine therapy for transient neonatal hypothyroidism. J Pediatr 1997; 130:478.
  62. Liu GT, Kay MD, Bienfang DC, Schatz NJ. Pseudotumor cerebri associated with corticosteroid withdrawal in inflammatory bowel disease. Am J Ophthalmol 1994; 117:352.
  63. Rickels MR, Nichols CW. Pseudotumor cerebri in patients with Cushing's disease. Endocr Pract 2004; 10:492.
  64. Ames D, Wirshing WC, Cokely HT, Lo LL. The natural course of pseudotumor cerebri in lithium-treated patients. J Clin Psychopharmacol 1994; 14:286.
  65. Dommisse J. Pseudotumor cerebri associated with lithium therapy in two patients. J Clin Psychiatry 1991; 52:239.
  66. Hexom B, Barthel RP. Lithium and pseudotumor cerebri. J Am Acad Child Adolesc Psychiatry 2004; 43:247.
  67. Levine SH, Puchalski C. Pseudotumor cerebri associated with lithium therapy in two patients. J Clin Psychiatry 1990; 51:251.
  68. Mukherjee A, Dutta P, Lahiri M, et al. Benign intracranial hypertension after nalidixic acid overdose in infants. Lancet 1990; 335:1602.
  69. Mushet GR. Pseudotumor and nitrofurantoin therapy. Arch Neurol 1977; 34:257.
  70. Francis PJ, Haywood S, Rigden S, et al. Benign intracranial hypertension in children following renal transplantation. Pediatr Nephrol 2003; 18:1265.
  71. Condulis N, Germain G, Charest N, et al. Pseudotumor cerebri: a presenting manifestation of Addison's disease. Clin Pediatr (Phila) 1997; 36:711.
  72. Alexandrakis G, Filatov V, Walsh T. Pseudotumor cerebri in a 12-year-old boy with Addison's disease. Am J Ophthalmol 1993; 116:650.
  73. Sheldon RS, Becker WJ, Hanley DA, Culver RL. Hypoparathyroidism and pseudotumor cerebri: an infrequent clinical association. Can J Neurol Sci 1987; 14:622.
  74. Segal L, Discepola M. Idiopathic intracranial hypertension and sickle cell disease: two case reports. Can J Ophthalmol 2005; 40:764.
  75. Nazir SA, Siatkowski RM. Pseudotumor cerebri in idiopathic aplastic anemia. J AAPOS 2003; 7:71.
  76. Purvin VA, Kawasaki A, Yee RD. Papilledema and obstructive sleep apnea syndrome. Arch Ophthalmol 2000; 118:1626.
  77. Marcus DM, Lynn J, Miller JJ, et al. Sleep disorders: a risk factor for pseudotumor cerebri? J Neuroophthalmol 2001; 21:121.
  78. Dave S, Longmuir R, Shah VA, et al. Intracranial hypertension in systemic lupus erythematosus. Semin Ophthalmol 2008; 23:127.
  79. Hershko AY, Berkun Y, Mevorach D, et al. Increased intracranial pressure related to systemic lupus erythematosus: a 26-year experience. Semin Arthritis Rheum 2008; 38:110.
  80. Green L, Vinker S, Amital H, et al. Pseudotumor cerebri in systemic lupus erythematosus. Semin Arthritis Rheum 1995; 25:103.
  81. Celebisoy N, Seçil Y, Akyürekli O. Pseudotumor cerebri: etiological factors, presenting features and prognosis in the western part of Turkey. Acta Neurol Scand 2002; 106:367.
  82. Palacio E, Rodero L, Pascual J. Topiramate-responsive headache due to idiopathic intracranial hypertension in Behçet syndrome. Headache 2004; 44:436.
  83. Glueck CJ, Iyengar S, Goldenberg N, et al. Idiopathic intracranial hypertension: associations with coagulation disorders and polycystic-ovary syndrome. J Lab Clin Med 2003; 142:35.
  84. Kesler A, Ellis MH, Reshef T, et al. Idiopathic intracranial hypertension and anticardiolipin antibodies. J Neurol Neurosurg Psychiatry 2000; 68:379.
  85. Leker RR, Steiner I. Anticardiolipin antibodies are frequently present in patients with idiopathic intracranial hypertension. Arch Neurol 1998; 55:817.
  86. Sussman J, Leach M, Greaves M, et al. Potentially prothrombotic abnormalities of coagulation in benign intracranial hypertension. J Neurol Neurosurg Psychiatry 1997; 62:229.
  87. Chang D, Nagamoto G, Smith WE. Benign intracranial hypertension and chronic renal failure. Cleve Clin J Med 1992; 59:419.
  88. Dotan G, Goldstein M, Stolovitch C, Kesler A. Pediatric Pseudotumor Cerebri Associated With Low Serum Levels of Vitamin A. J Child Neurol 2013; 28:1370.
  89. Obeid M, Price J, Sun L, et al. Facial palsy and idiopathic intracranial hypertension in twins with cystic fibrosis and hypovitaminosis A. Pediatr Neurol 2011; 44:150.
  90. Panozzo G, Babighian S, Bonora A. Association of xerophthalmia, flecked retina, and pseudotumor cerebri caused by hypovitaminosis A. Am J Ophthalmol 1998; 125:708.
  91. Lucidi V, Di Capua M, Rosati P, et al. Benign intracranial hypertension in an older child with cystic fibrosis. Pediatr Neurol 1993; 9:494.
  92. Biousse V, Bruce BB, Newman NJ. Update on the pathophysiology and management of idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2012; 83:488.
  93. Biousse V, Ameri A, Bousser MG. Isolated intracranial hypertension as the only sign of cerebral venous thrombosis. Neurology 1999; 53:1537.
  94. Lin A, Foroozan R, Danesh-Meyer HV, et al. Occurrence of cerebral venous sinus thrombosis in patients with presumed idiopathic intracranial hypertension. Ophthalmology 2006; 113:2281.
  95. Tehindrazanarivelo A, Evrard S, Schaison M, et al. Prospective study of cerebral sinus venous thrombosis in patients presenting with benign intracranial hypertension. Cerebrovasc Dis 1992; 2:22.
  96. Lee AG, Brazis PW. Magnetic resonance venography in idiopathic pseudotumor cerebri. J Neuroophthalmol 2000; 20:12.
  97. Higgins JN, Tipper G, Varley M, Pickard JD. Transverse sinus stenoses in benign intracranial hypertension demonstrated on CT venography. Br J Neurosurg 2005; 19:137.
  98. Bono F, Lupo MR, Lavano A, et al. Cerebral MR venography of transverse sinuses in subjects with normal CSF pressure. Neurology 2003; 61:1267.
  99. Farb RI, Vanek I, Scott JN, et al. Idiopathic intracranial hypertension: the prevalence and morphology of sinovenous stenosis. Neurology 2003; 60:1418.
  100. King JO, Mitchell PJ, Thomson KR, Tress BM. Manometry combined with cervical puncture in idiopathic intracranial hypertension. Neurology 2002; 58:26.
  101. Simister R, Bowler JV, Wilson PL, et al. Transverse venous sinus stenosis and intracranial hypertension: evidence for which comes first. J Neurol 2008; 255:601.
  102. McGonigal A, Bone I, Teasdale E. Resolution of transverse sinus stenosis in idiopathic intracranial hypertension after L-P shunt. Neurology 2004; 62:514.
  103. Higgins JN, Pickard JD. Lateral sinus stenoses in idiopathic intracranial hypertension resolving after CSF diversion. Neurology 2004; 62:1907.
  104. Rohr A, Dörner L, Stingele R, et al. Reversibility of venous sinus obstruction in idiopathic intracranial hypertension. AJNR Am J Neuroradiol 2007; 28:656.
  105. De Simone R, Marano E, Fiorillo C, et al. Sudden re-opening of collapsed transverse sinuses and longstanding clinical remission after a single lumbar puncture in a case of idiopathic intracranial hypertension. Pathogenetic implications. Neurol Sci 2005; 25:342.
  106. Baryshnik DB, Farb RI. Changes in the appearance of venous sinuses after treatment of disordered intracranial pressure. Neurology 2004; 62:1445.
  107. Bono F, Giliberto C, Mastrandrea C, et al. Transverse sinus stenoses persist after normalization of the CSF pressure in IIH. Neurology 2005; 65:1090.
  108. Riggeal BD, Bruce BB, Saindane AM, et al. Clinical course of idiopathic intracranial hypertension with transverse sinus stenosis. Neurology 2013; 80:289.
  109. Sugerman HJ, DeMaria EJ, Felton WL 3rd, et al. Increased intra-abdominal pressure and cardiac filling pressures in obesity-associated pseudotumor cerebri. Neurology 1997; 49:507.
  110. Sugerman HJ, Felton III WL 3rd, Sismanis A, et al. Continuous negative abdominal pressure device to treat pseudotumor cerebri. Int J Obes Relat Metab Disord 2001; 25:486.
  111. Friedman DI. Cerebral venous pressure, intra-abdominal pressure, and dural venous sinus stenting in idiopathic intracranial hypertension. J Neuroophthalmol 2006; 26:61.
  112. Digre KB, Varner MW, Corbett JJ. Pseudotumor cerebri and pregnancy. Neurology 1984; 34:721.
  113. Sahs AL, Joynt RJ. Brain swelling of unknown cause. Neurology 1954; 6:791.
  114. Wall M, Dollar JD, Sadun AA, Kardon R. Idiopathic intracranial hypertension. Lack of histologic evidence for cerebral edema. Arch Neurol 1995; 52:141.
  115. Bastin ME, Sinha S, Farrall AJ, et al. Diffuse brain oedema in idiopathic intracranial hypertension: a quantitative magnetic resonance imaging study. J Neurol Neurosurg Psychiatry 2003; 74:1693.
  116. Bicakci K, Bicakci S, Aksungur E. Perfusion and diffusion magnetic resonance imaging in idiopathic intracranial hypertension. Acta Neurol Scand 2006; 114:193.
  117. Owler BK, Higgins JN, Péna A, et al. Diffusion tensor imaging of benign intracranial hypertension: absence of cerebral oedema. Br J Neurosurg 2006; 20:79.
  118. Friedman DI, Streeten DH. Idiopathic intracranial hypertension and orthostatic edema may share a common pathogenesis. Neurology 1998; 50:1099.
  119. Jacobson DM, Berg R, Wall M, et al. Serum vitamin A concentration is elevated in idiopathic intracranial hypertension. Neurology 1999; 53:1114.
  120. Selhorst JB, Kulkantrakorn K, Corbett JJ, et al. Retinol-binding protein in idiopathic intracranial hypertension (IIH). J Neuroophthalmol 2000; 20:250.
  121. Warner JE, Bernstein PS, Yemelyanov A, et al. Vitamin A in the cerebrospinal fluid of patients with and without idiopathic intracranial hypertension. Ann Neurol 2002; 52:647.
  122. Tabassi A, Salmasi AH, Jalali M. Serum and CSF vitamin A concentrations in idiopathic intracranial hypertension. Neurology 2005; 64:1893.
  123. Warner JE, Larson AJ, Bhosale P, et al. Retinol-binding protein and retinol analysis in cerebrospinal fluid and serum of patients with and without idiopathic intracranial hypertension. J Neuroophthalmol 2007; 27:258.
  124. Libien J, Kupersmith MJ, Blaner W, et al. Role of vitamin A metabolism in IIH: Results from the idiopathic intracranial hypertension treatment trial. J Neurol Sci 2017; 372:78.
  125. Ooi LY, Walker BR, Bodkin PA, Whittle IR. Idiopathic intracranial hypertension: can studies of obesity provide the key to understanding pathogenesis? Br J Neurosurg 2008; 22:187.
  126. Bruce BB, Kedar S, Van Stavern GP, et al. Idiopathic intracranial hypertension in men. Neurology 2009; 72:304.
  127. Lee SSY, Nilagiri VK, Mackey DA. Sleep and eye disease: A review. Clin Exp Ophthalmol 2022; 50:334.
  128. Wong B, Fraser CL. Obstructive Sleep Apnea in Neuro-Ophthalmology. J Neuroophthalmol 2019; 39:370.
  129. Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri. Neurology 1997; 49:734.
  130. Lampl Y, Eshel Y, Kessler A, et al. Serum leptin level in women with idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry 2002; 72:642.
  131. Subramanian PS, Goldenberg-Cohen N, Shukla S, et al. Plasma ghrelin levels are normal in obese patients with idiopathic intracranial hypertension (pseudotumor cerebri). Am J Ophthalmol 2004; 138:109.
  132. Lee A, Kardon R, Wall M, Schlechte J. Endocrinologic abnormalities in pseudotumor cerebri in men. In: 28th Annual North American Neuro-Ophthalmology Society Meeting, Copper Mountain, CO 2002.
Topic 5254 Version 14.0

References

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟